Sebi has halted Par Drugs and Chemicals’ proposed slump sale of its core business to Phal-Jig Fine Chemicals, a promoter-related entity, due to concerns over valuation irregularities and shareholder communication. The regulator has ordered a re-examination of the business undertaking’s valuation and a fairness opinion, citing a significant erosion in PDCL’s market capitalization since the announcement.